Quantification of intraindividual variability and the influence of menstrual cycle phase on CYP2D6 activity as measured by dextromethorphan phenotyping

Pharmacogenetics

Volumn 8, Issue 5, 1998, Pages 403-410

  Kashuba, Angela D M ^a,f   Nafziger, Anne N ^a,b   Kearns, Gregory L ^c,d,e   Leeder, J Steven ^c,d,e   Shirey, Carol S ^b   Gotschall, Russell ^c   Gaedigk, Andrea ^c,d,e   Bertino Jr , Joseph S ^a,b  

^a BASSETT RESEARCH INSTITUTE   (United States)

^b Department of Medicine ^*  (United States)

^c CHILDREN S MERCY HOSPITAL   (United States)

^d UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^f The University of North Carolina at Chapel Hill   (United States)

Author keywords

CYP2D6; Dextromethorphan; Menstrual cycle; Phenotype

Indexed keywords

CYTOCHROME P450; DEBRISOQUINE 4 HYDROXYLASE; DEXTROMETHORPHAN; GUAIFENESIN;

ARTICLE; DRUG EXCRETION; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME POLYMORPHISM; FEMALE; FOLLICULAR PHASE; GENOTYPE; HORMONE RESPONSE; HUMAN; LUTEAL PHASE; MALE; MENSTRUAL CYCLE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHENOTYPE; PRIORITY JOURNAL; SEX DIFFERENCE; URINALYSIS;

ADULT; ANALYSIS OF VARIANCE; CYTOCHROME P-450 CYP2D6; DEXTROMETHORPHAN; DEXTRORPHAN; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOLLICULAR PHASE; GENOTYPE; HUMANS; LUTEAL PHASE; MALE; MENSTRUAL CYCLE; MIDDLE AGED; PHENOTYPE; SEX FACTORS;

EID: 0031665386     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199810000-00005     Document Type: Article

References (35)

1. Abdu-Aguye I, Dunlop D, Patel P, Turner P. Propranolol pharmacokinetics during the menstrual cycle. Postgrad Med J 1986; 62:1093-1095.
2. Abernethy DR, Greenblatt DJ, Shader RI. Imipramine and desipramine disposition in the elderly. J Pharmacol Exp Ther 1985; 232:183-188.
3. Brosen K, Gram LF. Clinical significance of the sparteine/debrisoquine oxidation polymorphism. Eur J Clin Pharmacol 1989; 36:537-547.
4. Chen ZR, Somogyi AA, Bochner F. Polymorphic O-demethylation of codeine. Lancet 1988; 2:914-915.
5. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31-41.
6. Daly AK, Armstrong M, Monkman SC, Idle ME, Idle JR. Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotypes. Pharmacogenetics 1991; 1:33-41.
7. Devine BJ. Gentamicin pharmacokinetics. Drug Intell Clin Pharm 1974; 8:650-655.
8. Eichelbaum M, Gross AS. The genetic polymorphism of debrisoquine/sparteine metabolism - clinical aspects. Pharmacol Ther 1990; 46:377-394.
9. Food and Drug Administration. Guideline for the study and evaluation of gender differences in the clinical evaluation of drugs. Federal Reg 1993; 58:39406-39416.
10. Gerdin E, Rand A. N-demethylation of ethylmorphine in pregnant and non-pregnant women and in men: an evaluation of the effects of sex steroids. Br J Clin Pharmacol 1992; 34:250-255.
11. Gex-Fabry M, Balant-Gorgia AE, Balant LP, Garrone GL. Clomipramine metabolism: model-based analysis of variability factors from drug monitoring data. Clin Pharmacokinet 1990; 19:241-255.
12. Gilmore DA, Gal J, Gerber JG, Nies AS. Age and gender influence the stereoselective pharmacokinetics of propranolol. J Pharmacol Exp Ther 1992; 261:1181-1186.
13. Griese EU, Zanger UM, Brudermanns, U, Gaedigk A, Mikus G, Mrike K, et al. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics 1998; 8:15-26.
14. Guidicelli JF, Tillement JP. Influence of sex on drug kinetics in man. Clin Pharmacokinet 1977; 2:157-166.
15. Harris RZ, Benet LZ, Schwartz JB. Gender effects in pharmacokinetics and pharmacodynamics. Drugs 1995; 50:222-239.
16. Jacqz-Aigrain H, Funck-Brentano C, Cresteil T. CYP2D6- and CYP3A-dependent metabolism of dextromethorphan in humans. Pharmacogenetics 1993; 3:197-204.
17. Johannson I, Lundquist K, Dahl ML, Ingelman-Sundberg M. PCR-based genotyping for duplicated and deleted CYP2D6 genes. Pharmacogenetics 1996; 6:351-355.
18. Kupfer A, Schmid B, Preisig R, Pfaff G. Dextromethorphan as a safe probe for debrisoquine hydroxylation polymorphism. Lancet 1984; 2:517-518.
19. Lam YW, Rodriguez SY. High-performance liquid chromatography determination of dextromethorphan and dextrorphan for oxidation phenotyping by fluorescence and ultraviolet detection. Ther Drug Monit 1993; 15:300-304.
20. Marez D, Legrand M, Sabbagh N, Lo Guidice JM, Spire C, Latiffe JJ, et al. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 1997; 7:193-202.
21. Meyer UA. The molecular basis of genetic polymorphisms of drug metabolism. J Pharm Pharmacol 1994; 46 (Suppl 1):409-415.
22. Okey AB. Enzyme induction in the cytochrome P-450 system. Pharmacol Ther 1990; 45:241-298.
23. Otton SV, Schadel M, Cheung SW, Kaplan HL, Busto UE, Sellers EM. CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone. Clin Pharmacol Ther 1993; 54:463-472.
24. Otton SV, Wu D, Joffe RT, Cheung SW, Sellers EM. Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin Pharmacol Ther 1993; 53:401-409.
25. Park YH, Kullberg MP, Hinsvark ON. Quantitative determination of dextromethorphan and three metabolites in urine by reverse-phase high-performance liquid chromatography. J Pharm Sci 1984; 73:24-29.
26. Pfaff G, Briegel P, Lamprecht I. Interindividual variation in the metabolism of dextromethorphan. Int J Pharm 1983; 14:173-189.
27. Sachse C, Brockmoller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997; 60:284-295.
28. Schmid B, Bircher J, Preisig R, Kupfer A. Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation. Clin Pharmacol Ther 1985; 38:618-624.
29. Schmider J, Greenblatt DJ, Fogelman SM, von Moltke LL, Shader RI. Metabolism of dextromethorphan in vitro: involvement of cytochromes P450 2D6 and 3A3/4, with a possible role of 2E1. Biopharmaceut Drug Dispos 1997; 18:227-240.
30. Skett P. Biochemical basis of sex differences in drug metabolism. Pharmacol Ther 1988; 38:269-304.
31. Skett P. Role of hormones in the control of mixed-function oxidases. Biochem Soc Trans 1990; 18:24-26.
32. SYSTAT. SYSTAT user's guide. Evanston, IL: SYSTAT Intelligent software Inc.: 1990.
33. Wilson K. Sex related differences in drug disposition in man. Clin Pharmacokinet 1984; 9:189-202.
34. Wu D, Otton SV, Sproule BA. Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone. Br J Clin Pharmacol 1993; 35:30-34.
35. Zimmermann T, Schlenk R, Pfaff G, Lach P, Wildfeuer A. Prediction of phenotype for dextromethorphan O-demethylation by using polymerase chain reaction in healthy volunteers. Arzneim.-Forsch./Drug Res 1995; 45:41-43.